Grant of Options

RNS Number : 6906L
MaxCyte, Inc.
20 July 2017
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

 

Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that it has granted, effective July 14, 2017, a total of 686,400 options of common stock in the Company ("Common Stock") to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

 

Option Grants to PDMRs


Doerfler, Doug

296,000

Holtz, Ron

134,800

Madhusudan, Peshwa

136,100

Thompson, J. Stark

23,900

Mandell, Art

23,900

Erck, Stan

23,900

Brooke, Will

23,900

Johnston, John

23,900

Total

686,400

 

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on July 14, 2017, of 242.50 pence.

 

 

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.   For more information, visit http://www.maxcyte.com/

 

 ###

 

 

MaxCyte Inc.


Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

 

Nominated Adviser and Broker

Panmure Gordon


Freddy Crossley (Corporate Finance)

Duncan Monteith

Ryan McCarthy

Tom Salvesen (Corporate Broking)

+44 (0) 20 7886 2500

 

 

Financial PR Adviser

Consilium Strategic Communications


Mary-Jane Elliott

Chris Welsh

Lindsey Neville

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

 

 1

Details of the person discharging managerial responsibilities / person closely associated 

a)

Names 

Doerfler, Doug

Holtz, Ron

Madhusudan, Peshwa

Thompson, J. Stark

Mandell, Art

Erck, Stan

Brooke, Will

Johnston, John

2

Reason for the notification

a)

Position/status

 

Doerfler, Doug - CEO and Director

Holtz, Ron - CFO and Director

Madhusudan, Peshwa - CSO

Thompson, J. Stark - Non-executive Chairman

Mandell, Art - Non-executive Director

Erck, Stan - Non-executive Director

Brooke, Will - Non-executive Director

Johnston, John - Non-executive Director

b)

Initial notification /Amendment 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Grant of Options over Shares of Common Stock

b)

Identification code  

US57777K1060

c)

Nature of the transactions  

 

Grant of Options to PDMRs

d)

 

Price(s) and volume(s)

Doerfler, Doug - 296,000 at an exercise price of 242.50 pence

Holtz, Ron - 134,800 at an exercise price of 242.50 pence

Madhusudan, Peshwa - 136,100 at an exercise price of 242.50 pence

Thompson, J. Stark - 23,900 at an exercise price of 242.50 pence

Mandell, Art - 23,900 at an exercise price of 242.50 pence

Erck, Stan - 23,900 at an exercise price of 242.50 pence

Brooke, Will - 23,900 at an exercise price of 242.50 pence

Johnston, John - 23,900 at an exercise price of 242.50 pence

d)

 

Aggregated information 

- Aggregated volume

- Price

 n/a 

e)

 

Date of the transactions 

14 July 2017

f) 

Place of the transaction

Outside a trading venue

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAXXEAEEXEFF
UK 100

Latest directors dealings